Chapter 47. Hematopoietic Cell Transplantation from Unrelated Donors

  1. Frederick R. Appelbaum MD Member Director Professor Head3,4,
  2. Stephen J. Forman MD Director Staff Physician5,6,
  3. Robert S. Negrin MD Professor of Medicine Chief7 and
  4. Karl G. Blume MD, FACP Emeritus Professor of Medicine7,8
  1. Effie W. Petersdorf MD Member Professor of Medicine1,2

Published Online: 5 MAR 2009

DOI: 10.1002/9781444303537.ch47

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

How to Cite

Petersdorf, E. W. (2009) Hematopoietic Cell Transplantation from Unrelated Donors, in Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition (eds F. R. Appelbaum, S. J. Forman, R. S. Negrin and K. G. Blume), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303537.ch47

Editor Information

  1. 3

    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

  2. 4

    Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington, USA

  3. 5

    Department of Hematology and Hematopoietic Cell Transplantation, Duarte, California, USA

  4. 6

    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA

  5. 7

    Division of Blood and Marrow Transplantation, Stanford University, Stanford, California, USA

  6. 8

    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University, School of Medicine, Stanford, California, USA

Author Information

  1. 1

    Fred Hutchinson Cancer Research Center, Seattle, WA, USA

  2. 2

    University of Washington School of Medicine, Seattle, WA, USA

Publication History

  1. Published Online: 5 MAR 2009
  2. Published Print: 27 FEB 2009

ISBN Information

Print ISBN: 9781405153485

Online ISBN: 9781444303537

SEARCH

Keywords:

  • hematopoietic cell transplantation from unrelated donors;
  • acute myeloid leukemia;
  • chronic myeloid leukemia;
  • HLA system;
  • alleles and antigens;
  • KIR haplotypes and activating receptors;
  • Phase III: inflammatory effectors

Summary

This chapter contains sections titled:

  • Introduction

  • Role of unrelated donor HCT in the treatment of hematologic malignancies

  • Optimizing unrelated HCT: genetic factors that influence outcome

  • Conclusion

  • References